Shorter antibiotic regime appears effective for drug-resistant TB
A shorter nine-month course of antibiotics might be just as effective in fighting multi-drug-resistant tuberculosis (MDR TB) as the current two-year standard, according to early results from an international clinical trial, per the New York Times. The trial saw a 78% success rate, compared with 81% for the two-year treatment.
Why it matters: Each year, nearly 500,000 people become sick with MDR TB, leading to about 200,000 deaths, according to the Centers for Disease Control and Prevention. A shorter medication regime would benefit the infected populace, which is centered in the developing world.